Three distinct classes of regulatory cytokines control endothelial cell MHC antigen expression. Interactions with immune gamma interferon differentiate the effects of tumor necrosis factor and lymphotoxin from those of leukocyte alpha and fibroblast beta interferons - PubMed (original) (raw)
Three distinct classes of regulatory cytokines control endothelial cell MHC antigen expression. Interactions with immune gamma interferon differentiate the effects of tumor necrosis factor and lymphotoxin from those of leukocyte alpha and fibroblast beta interferons
L A Lapierre et al. J Exp Med. 1988.
Abstract
Recombinant preparations of TNF and lymphotoxin (LT) increase the expression of class I MHC antigens on cultured human endothelial cells (EC) without inducing expression of class II antigens. These actions are similar to those of rIFN-alpha or rIFN-beta. However, TNF and LT differ from IFN-alpha/beta in that the former synergize with IFN-gamma for class I regulation whereas the latter do not. Furthermore, LT or TNF do not affect IFN-gamma-mediated class II induction at optimal class I inducing concentrations (100 U/ml), whereas IFN-alpha and IFN-beta (at their optimal concentrations of 1,000 U/ml) are strikingly inhibitory. LT and TNF also can further increase expression of class I antigens on cells already maximally stimulated by IFN-alpha or IFN-beta. A recombinant preparation of IL-6 (formerly called 26-kD protein, IFN-beta 2, or B cell stimulating factor 2) was without effect on class I expression in EC. These data make it seem unlikely that the actions of LT or TNF on EC expression of MHC antigens are mediated through autocrine or paracrine production of IFN-alpha, IFN-beta or IL-6. More importantly, they suggest that LT or TNF are more likely to be immunostimulatory, whereas IFN-alpha or IFN-beta are more likely to be immunoinhibitory in vivo, a consideration of potential relevance for cytokine administration to various patient populations.
Similar articles
- Regulation of human lung fibroblast glycosaminoglycan production by recombinant interferons, tumor necrosis factor, and lymphotoxin.
Elias JA, Krol RC, Freundlich B, Sampson PM. Elias JA, et al. J Clin Invest. 1988 Feb;81(2):325-33. doi: 10.1172/JCI113324. J Clin Invest. 1988. PMID: 2448341 Free PMC article. - Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species.
Pober JS, Lapierre LA, Stolpen AH, Brock TA, Springer TA, Fiers W, Bevilacqua MP, Mendrick DL, Gimbrone MA Jr. Pober JS, et al. J Immunol. 1987 May 15;138(10):3319-24. J Immunol. 1987. PMID: 3494766 - Effects of tumour necrosis factor and related cytokines on vascular endothelial cells.
Pober JS. Pober JS. Ciba Found Symp. 1987;131:170-84. doi: 10.1002/9780470513521.ch12. Ciba Found Symp. 1987. PMID: 3330009 Review. - An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus.
Rabinovitch A. Rabinovitch A. Diabetes Metab Rev. 1998 Jun;14(2):129-51. doi: 10.1002/(sici)1099-0895(199806)14:2<129::aid-dmr208>3.0.co;2-v. Diabetes Metab Rev. 1998. PMID: 9679667 Review.
Cited by
- Tumor necrosis factor regulation of major histocompatibility complex gene expression.
Johnson DR, Pober JS. Johnson DR, et al. Immunol Res. 1991;10(2):141-55. doi: 10.1007/BF02918161. Immunol Res. 1991. PMID: 1655923 Review. No abstract available. - Differential distribution and modulation of expression of alpha 1/beta 1 integrin on human endothelial cells.
Defilippi P, van Hinsbergh V, Bertolotto A, Rossino P, Silengo L, Tarone G. Defilippi P, et al. J Cell Biol. 1991 Aug;114(4):855-63. doi: 10.1083/jcb.114.4.855. J Cell Biol. 1991. PMID: 1869591 Free PMC article. - Endothelial cells in allograft rejection.
Al-Lamki RS, Bradley JR, Pober JS. Al-Lamki RS, et al. Transplantation. 2008 Nov 27;86(10):1340-8. doi: 10.1097/TP.0b013e3181891d8b. Transplantation. 2008. PMID: 19034000 Free PMC article. Review. - Role of Exercise Intensity on Th1/Th2 Immune Modulations During the COVID-19 Pandemic.
Supriya R, Gao Y, Gu Y, Baker JS. Supriya R, et al. Front Immunol. 2021 Dec 22;12:761382. doi: 10.3389/fimmu.2021.761382. eCollection 2021. Front Immunol. 2021. PMID: 35003073 Free PMC article. Review.
References
- J Immunol. 1985 Jul;135(1):25-33 - PubMed
- Proc Natl Acad Sci U S A. 1983 Aug;80(15):4654-8 - PubMed
- J Clin Invest. 1986 May;77(5):1596-605 - PubMed
- Immunobiology. 1984 Dec;168(3-5):453-69 - PubMed
- J Immunol. 1985 May;134(5):3100-3 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials